Gilead Sciences Inc (GILD)
89.80
+1.17
(+1.32%)
USD |
NASDAQ |
Nov 21, 16:00
89.80
0.00 (0.00%)
After-Hours: 20:00
Gilead Sciences Enterprise Value: 128.58B for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 128.58B |
| November 19, 2024 | 127.49B |
| November 18, 2024 | 128.37B |
| November 15, 2024 | 128.30B |
| November 14, 2024 | 132.92B |
| November 13, 2024 | 133.57B |
| November 12, 2024 | 135.71B |
| November 11, 2024 | 139.05B |
| November 08, 2024 | 138.47B |
| November 07, 2024 | 140.14B |
| November 06, 2024 | 132.40B |
| November 05, 2024 | 130.57B |
| November 04, 2024 | 130.09B |
| November 01, 2024 | 129.68B |
| October 31, 2024 | 128.82B |
| October 30, 2024 | 128.14B |
| October 29, 2024 | 127.88B |
| October 28, 2024 | 128.72B |
| October 25, 2024 | 129.02B |
| October 24, 2024 | 128.75B |
| October 23, 2024 | 126.82B |
| October 22, 2024 | 127.98B |
| October 21, 2024 | 125.65B |
| October 18, 2024 | 126.18B |
| October 17, 2024 | 126.98B |
| Date | Value |
|---|---|
| October 16, 2024 | 126.22B |
| October 15, 2024 | 125.06B |
| October 14, 2024 | 124.10B |
| October 11, 2024 | 123.98B |
| October 10, 2024 | 123.63B |
| October 09, 2024 | 125.46B |
| October 08, 2024 | 124.30B |
| October 07, 2024 | 123.33B |
| October 04, 2024 | 123.53B |
| October 03, 2024 | 123.00B |
| October 02, 2024 | 123.71B |
| October 01, 2024 | 122.72B |
| September 30, 2024 | 122.59B |
| September 27, 2024 | 124.59B |
| September 26, 2024 | 123.88B |
| September 25, 2024 | 122.84B |
| September 24, 2024 | 124.81B |
| September 23, 2024 | 125.06B |
| September 20, 2024 | 125.00B |
| September 19, 2024 | 124.95B |
| September 18, 2024 | 124.94B |
| September 17, 2024 | 123.89B |
| September 16, 2024 | 124.03B |
| September 13, 2024 | 123.59B |
| September 12, 2024 | 124.03B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
76.35B
Minimum
Dec 30 2020
140.14B
Maximum
Nov 07 2024
106.25B
Average
107.16B
Median
Enterprise Value Benchmarks
| Eli Lilly and Co | 742.91B |
| Merck & Co Inc | 270.08B |
| Pfizer Inc | 198.27B |
| Vertex Pharmaceuticals Inc | 109.68B |
| Amgen Inc | 206.13B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.253B |
| Revenue (Quarterly) | 7.545B |
| Total Expenses (Quarterly) | 4.402B |
| EPS Diluted (Quarterly) | 1.00 |
| Gross Profit Margin (Quarterly) | 79.14% |
| Profit Margin (Quarterly) | 16.61% |
| Earnings Yield | 0.10% |
| Operating Earnings Yield | 6.80% |
| Normalized Earnings Yield | 4.990 |